Literature DB >> 23108200

Management of CAH during pregnancy: optimizing outcomes.

Selma Feldman Witchel1.   

Abstract

PURPOSE OF REVIEW: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive disorders. In the past, pregnancy was considered to be unlikely for women with CAH, particularly the classical forms. The purpose of this review is to provide current information regarding the pathophysiology of CAH, factors relevant for female and male fertility, and recommendations for management during pregnancy. RECENT
FINDINGS: Individuals with CAH, both female and male, have reduced fertility. For women, chronic anovulation, elevated progestin levels, and aberrant endometrial implantation have been identified as reasons for the subfertility. Testicular adrenal rest tumors, oligospermia, and hypogonadotropic hypogonadism are frequently associated with subfertility in men with all forms of CAH.
SUMMARY: Adequate suppression of progesterone appears to be an essential aspect of preconception management for women. Most importantly, treatment needs to be individualized. Awareness of these factors and appropriate therapeutic interventions can lead to successful outcome defined as a healthy live born infant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108200     DOI: 10.1097/MED.0b013e32835a1a2e

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  10 in total

Review 1.  Congenital Adrenal Hyperplasia.

Authors:  Selma Feldman Witchel
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-04-24       Impact factor: 1.814

2.  Congenital adrenal hyperplasia and pregnancy.

Authors:  Soulmaz Shorakae; Helena Teede
Journal:  BMJ Case Rep       Date:  2013-08-05

Review 3.  Clinical outcomes and characteristics of P30L mutations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mirjana Kocova; Violeta Anastasovska; Henrik Falhammar
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

4.  The relationship between adolescent obesity and pelvis dimensions in adulthood: a retrospective longitudinal study.

Authors:  Jan M Novak; Jaroslav Bruzek; Hana Zamrazilova; Marketa Vankova; Martin Hill; Petr Sedlak
Journal:  PeerJ       Date:  2020-05-11       Impact factor: 2.984

5.  Miscarriages in families with an offspring that have classic congenital adrenal hyperplasia and 21-hydroxylase deficiency.

Authors:  Helmuth G Dörr; Johannes Hess; Theresa Penger; Michaela Marx; Patricia Oppelt
Journal:  BMC Pregnancy Childbirth       Date:  2018-11-23       Impact factor: 3.007

6.  Congenital adrenal hyperplasia with homozygous and heterozygous mutations: a rare family case report.

Authors:  Tiantian Cheng; Jing Liu; Wenwen Sun; Guangyao Song; Huijuan Ma
Journal:  BMC Endocr Disord       Date:  2022-03-07       Impact factor: 2.763

Review 7.  Reproductive outcomes of female patients with congenital adrenal hyperplasia due to 21-hydroxylase defi ciency.

Authors:  Mouna Feki Mnif; Mahdi Kamoun; Faten Hadj Kacem; Fatma Mnif; Nadia Charfi; Basma Ben Naceur; Nabila Rekik; Mohamed Abid
Journal:  Indian J Endocrinol Metab       Date:  2013-09

8.  Nonclassical Congenital Adrenal Hyperplasia and Pregnancy.

Authors:  Neslihan Cuhaci; Cevdet Aydın; Ahmet Yesilyurt; Ferda Alpaslan Pınarlı; Reyhan Ersoy; Bekir Cakir
Journal:  Case Rep Endocrinol       Date:  2015-10-08

Review 9.  Caring for individuals with a difference of sex development (DSD): a Consensus Statement.

Authors:  Martine Cools; Anna Nordenström; Ralitsa Robeva; Joanne Hall; Puck Westerveld; Christa Flück; Birgit Köhler; Marta Berra; Alexander Springer; Katinka Schweizer; Vickie Pasterski
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

10.  Successful pregnancy and live birth in woman with congenital adrenal hyperplasia: A case report.

Authors:  Wei Xiong; Guiqiong Huang; Xiaodong Wang; Shiqiao Tan
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.